Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study

Autor: Peter Bult, Caroline Weltens, Lorenzo Livi, B. Vieites, D. Limon, Prantesh Jain, Yazid Belkacemi, V.L. Chiang, N. Kurman, Philip Poortmans, Kevin Ko, Nicole L. Simone, James B. Yu, P. Navarria, Timothy M. Zagar, J. Lopez-Guerra, Brigitta G. Baumert, Orit Kaidar-Person, Icro Meattini, I. Kindts, R. Steffens
Rok vydání: 2018
Předmět:
Adult
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Receptor Status
Receptor
ErbB-2
Estrogen receptor
Breast Neoplasms
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
0302 clinical medicine
Breast cancer
Internal medicine
Progesterone receptor
Biomarkers
Tumor
medicine
Humans
Neoplasm Metastasis
skin and connective tissue diseases
Receptor
In Situ Hybridization
Fluorescence
Aged
Aged
80 and over
Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]
medicine.diagnostic_test
Brain Neoplasms
business.industry
Estrogen Receptor alpha
Middle Aged
medicine.disease
Primary tumor
Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
Gene Expression Regulation
Neoplastic
030104 developmental biology
030220 oncology & carcinogenesis
Female
Receptors
Progesterone
business
Estrogen receptor alpha
Fluorescence in situ hybridization
Zdroj: Breast Cancer Research and Treatment, 167, 2, pp. 479-483
Breast Cancer Research and Treatment, 167, 479-483
ISSN: 0167-6806
Popis: Discordances between the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), expression between primary breast tumors and their subsequent brain metastases (BM) were investigated in breast cancer patients. We collected retrospective data from 11 institutions in 8 countries in a predefined-standardized format. Receptor status (positive or negative) was determined according to institutional guidelines (immunohistochemically and/or fluorescence in situ hybridization). The study was subject to each institution’s ethical research committee. A total of 167 breast cancer patients with BM were included. 25 patients out of 129 with a complete receptor information from both primary tumor and BM (ER, PR, HER2) available, had a change in receptor status: 7 of 26 (27%) ER/PR-positive/HER2-negative primaries (3 gained HER2; 4 lost expression of ER/PR); 10 of 31 (32%) ER/PR-positive/HER2-positive primaries (4 lost ER/PR only; 3 lost HER2 only; 3 lost both ER/PR and HER2); one of 33 (3%) ER/PR-negative receptor/HER2-positive primaries (gained ER); and 7 of 39 (18%) triple-negative primaries (5 gained ER/PR and 2 gained HER2). The majority of breast cancer patients with BM in this series had primary HER2-enriched tumors, followed by those with a triple-negative profile. One out of 5 patients had a receptor discrepancy between the primary tumor and subsequent BM. Therefore, we advise receptor status assessment of BM in all breast cancer patients with available histology as it may have significant implications for therapy.
Databáze: OpenAIRE
Externí odkaz: